BREATHTEK UBT FOR H-PYLORI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BREATHTEK UBT FOR H-PYLORI (BREATHTEK UBT FOR H-PYLORI).
BREATHTEK UBT is a 13C-urea breath test that detects Helicobacter pylori infection. The patient ingests 13C-labeled urea; if H. pylori is present, its urease enzyme hydrolyzes urea to 13CO2, which is absorbed and exhaled, allowing detection by mass spectrometry or infrared spectroscopy.
| Metabolism | Not applicable; the test involves oral administration of 13C-urea, which is metabolized by bacterial urease if H. pylori is present, or excreted unchanged in urine. No hepatic metabolism. |
| Excretion | BreathTek UBT (13C-urea) is metabolized by H. pylori urease to 13CO2, which is exhaled. Unmetabolized urea is renally excreted; renal elimination of unchanged 13C-urea accounts for approximately 20-30% of the administered dose, with the remainder exhaled as 13CO2 within 60 minutes. Fecal/biliary excretion is negligible. |
| Half-life | 13C-urea has a plasma half-life of approximately 0.5–1 hour. The 13CO2 exhaled peak occurs at 20–30 minutes, reflecting rapid urease hydrolysis. The terminal half-life is not clinically relevant as the breath test relies on early exhalation kinetics. |
| Protein binding | Minimal (<5%) protein binding; 13C-urea is a small, hydrophilic molecule that distributes freely in body water. |
| Volume of Distribution | Approximately 0.3–0.5 L/kg (total body water). Reflects rapid distribution in extracellular and intracellular compartments. |
| Bioavailability | Oral: 100% bioavailable as 13C-urea is absorbed in the small intestine and enters systemic circulation unchanged. Complete absorption is assumed for the diagnostic purpose. |
| Onset of Action | Oral administration: Detection of 13CO2 in breath begins within 10–15 minutes; peak occurs at 20–30 minutes. The test measures urease activity, not a pharmacodynamic effect. |
| Duration of Action | Exhaled 13CO2 returns to baseline within 60–90 minutes. The clinical duration is limited to the breath collection period (30 minutes post-dose). Not used for continuous therapy. |
75 mg of 13C-urea oral powder dissolved in 75 mL water, administered once after a baseline breath sample; a second breath sample is collected 30 minutes after dosing.
| Dosage form | FOR SOLUTION |
| Renal impairment | No dosage adjustment required for renal impairment as the drug is a diagnostic agent with minimal systemic absorption. |
| Liver impairment | No dosage adjustment required for hepatic impairment; the test relies on urease activity in the stomach, not hepatic function. |
| Pediatric use | For children aged 3–11 years: 50 mg of 13C-urea powder dissolved in 50 mL water; for children 12 years and older: adult dose of 75 mg. |
| Geriatric use | No specific dose adjustment for elderly patients; use standard adult dose as the test is well-tolerated and systemic exposure is negligible. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BREATHTEK UBT FOR H-PYLORI (BREATHTEK UBT FOR H-PYLORI).
| Breastfeeding | 13C-urea is endogenous and expected to be present in breast milk. M/P ratio unknown. Excretion is minimal and considered safe. Consult physician before use. |
| Teratogenic Risk | BREATHTEK UBT FOR H-PYLORI contains 13C-urea, a non-radioactive isotope. No teratogenic effects reported in animal studies; limited human data. Generally considered low risk, but use only if clearly needed. No first trimester-specific risks identified. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Known hypersensitivity to 13C-urea or any component of the test.","Previous gastrectomy (altered anatomy may affect test accuracy)."]
| Precautions | ["May cause false-negative results in patients taking proton pump inhibitors, bismuth preparations, or antibiotics within 2-4 weeks prior to testing.","False-negative results may occur in patients with active gastrointestinal bleeding or conditions that delay gastric emptying.","The test is non-radioactive and generally safe, but rare allergic reactions to the substrate have been reported."] |
| Food/Dietary | No direct food interactions; however, the test requires fasting for 6 hours prior to administration. Consumption of food or beverages (including water) before the test can cause false negatives or unreliable results. After the test, no dietary restrictions. |
Loading safety data…
| No specific monitoring required. Ensure accurate test performance. Monitor maternal symptoms of H. pylori infection if untreated. |
| Fertility Effects | No known effects on fertility. 13C-urea does not affect reproductive function. |
| Clinical Pearls | BREATHTEK UBT is a urea breath test for detecting Helicobacter pylori infection. It relies on the organism's urease activity; false negatives can occur with recent use of proton pump inhibitors, bismuth compounds, or antibiotics (within 2-4 weeks). The test should be performed after a 6-hour fast. A positive test indicates active infection; a negative test suggests either no infection or suppression of urease activity. Confirm positive results with stool antigen or histology if clinical suspicion persists. |
| Patient Advice | Do not eat or drink anything for at least 6 hours before the test. · Avoid antibiotics, bismuth preparations, and proton pump inhibitors for at least 2 weeks prior (4 weeks for antibiotics). · Inform your doctor if you have had a gastrectomy or are taking acid-suppressing medications. · The test involves drinking a solution containing urea and then providing breath samples after 15-30 minutes. · The test is safe; side effects are rare but may include mild bloating or nausea. |